Loading chat...
WA HB1741
Bill
Status
1/30/2025
Primary Sponsor
My-Linh Thai
Click for details
AI Summary
-
Health carriers must cover initial three monthly courses of intravenous immunoglobulin (IVIG) therapy for PANDAS and PANS treatment, with additional courses covered when deemed medically necessary by the treating provider, effective January 1, 2026
-
Coverage requires that two or more less intensive treatments (which may be tried concurrently) were not effective, not tolerated, or did not produce sustained symptom improvement as measured by validated instruments
-
A pediatric subspecialist must be consulted and both the subspecialist and the patient's primary care provider must recommend the treatment; adult subspecialists may be consulted for adolescent or adult patients
-
Teleconsultation is permitted for the required subspecialist consultation
-
Health carriers may require clinical reevaluation of patients at three-month intervals; public employee health plans under chapter 41.05 RCW are excluded from these requirements
Legislative Description
Expanding access to treatment of pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections and pediatric acute-onset neuropsychiatric syndrome.
Last Action
By resolution, reintroduced and retained in present status.
1/12/2026